Compare Organon & Co. Common Stock (OGN) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Wells Fargo & Co — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Wells Fargo & Co trades at $80.9 (market cap $242.35B). The key difference: Wells Fargo & Co is far larger — about 66.9× Organon & Co. Common Stock's market cap, and Wells Fargo & Co pays the higher dividend (2.48%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Wells Fargo & Co for 88 Days on average.
| OGN | WFC | |
|---|---|---|
Market Cap | $3.62B | $242.35B |
Volume | 2,892,999 | 25,561,701 |
Sector | Health | Financials |
52-Week High | $13.81 | $96.40 |
52-Week Low | $5.70 | $73.42 |
Typical Hold Time | 0 Days | 88 Days |
Enterprise Value | $11.04B | $424.64B |
Dividend Yield | 0.58% | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Wells Fargo (WFC) trades at $80.91, down 2.88% on the day, amid mixed technical signals with a bullish overall trend but bearish moving averages. The bank shows strong fundamentals with a P/E of 11.74, net income margin of 25.97%, and consistent earnings beats in recent quarters. Recent positive developments include a credit rating upgrade to 'A-' by S&P (Zacks Investment Research, 2026-10-01) and renewed technology agreements supporting mortgage servicing.
The stock presents a value opportunity with a consensus price target of $98.75, implying 22% upside, supported by analyst bullishness (46.66% buy ratings). Key risks include volatile cash flows, with operating cash flow negative in 2025, and sensitivity to interest rate changes as highlighted by recent Fed hikes (Reuters, 2026-09-23).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
